Nutriband, Inc. NTRB 深 滬
已收盤 02-06 16:00:00 美东时间
4.35
+0.005
+0.12%
華盛通- 最 高4.50
- 今 開4.30
- 成交量 1.29万股
- 最 低 4.30
- 昨 收 4.345
- 總市值 5296.07万
- 52周最高 11.6779
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 4.17
- 委 比 -65.58%
- 總股本 1217.49万
- 歷史最高 11.78
- 量 比 0.89
- 振 幅 4.60%
- 歷史最低 1.53
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. reported on 2025 achievements including advancing their AVERSA™ Fentanyl patch towards commercialization, securing patents, and enhancing shareholder value through strategic moves like selling a subsidiary and issuing preferred stock dividends. The company also joined four prominent indexes and anticipates reduced stock volatility as warrants from their 2021 IPO expire in 2026. AVERSA™ aims to be the world's first abuse-deterrent o...
2025-12-31 12:00
What's Going On With Nutriband Stock Monday?
Nutriband shares are trading higher Monday after the company it signed an agreement to sell the majority stake of its subsidiary, Pocono Pharmaceutical, to EarthVision Bio.
2025-12-30 05:40
Nutriband shares are trading higher after the company announced it signed an agreement to sell the majority stake of its subsidiary, Pocono Pharmaceutical, to EarthVision Bio.
Nutriband shares are trading higher after the company announced it signed an ag...
2025-12-30 01:33
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock increased by 25.5% to $25.9...
2025-12-30 01:05
Nutriband Responds To Executive Order Designating Illicit Fentanyl As A Weapon Of Mass Destruction, Differentiates Prescription Transdermal Fentanyl And Highlights Aversa Fentanyl Development
Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which
2025-12-18 20:07
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
US designates illicit fentanyl as a weapon of mass destruction due to its severe dangers. However, FDA-approved prescription fentanyl patches remain critical for opioid-tolerant patients with severe chronic pain. Nutriband Inc., in collaboration with Kindeva, is developing AVERSA™ FENTANYL, the first abuse-deterrent opioid patch, incorporating aversive agents to prevent misuse and accidental exposure. The technology aims to improve safety while e...
2025-12-18 12:00
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
<p>Nutriband met with the US FDA to discuss the Chemistry, Manufacturing, and Controls plans for its abuse-deterrent fentanyl patch, AVERSA™ FENTANYL. The FDA provided feedback on the regulatory pathway, manufacturing strategy, product specifications, and abuse-deterrent studies. Nutriband is incorporating this feedback into its development program ahead of an IND filing for a Human Abuse Potential clinical study. AVERSA™ combines Nutriband's abu...
2025-10-28 11:00
Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei
2025-10-27 19:09
Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband Inc. announced that founder Gareth Sheridan has returned as CEO, succeeding Co-Founder Serguei Melnik who led the company from August 10 to October 27. Sheridan will guide Nutriband toward the 2026 NDA filing for AVERSA Fentanyl, an innovative abuse-deterrent opioid patch designed to reduce misuse and accidental exposure. Targeting annual U.S. sales of $80–200 million, AVERSA Fentanyl addresses a global need for safer pain management. T...
2025-10-27 11:00
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband has partnered with Brand Institute to develop a worldwide commercial brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology, which incorporates aversive agents into transdermal patches to prevent abuse, misuse, and accidental exposure of opioids. Brand Institute, a global leader in pharmaceutical brand naming, w...
2025-10-10 11:00
